Controlled substances: research.
- Streamlines the approval process for research involving Schedule I and II controlled substances in California.
- Requires the Research Advisory Panel to expedite review of projects with federal approval and peer review.
- Extends authorization for closed research review sessions through January 1, 2029.
- Establishes procedures for withdrawing research approval if safety concerns or drug diversion arise.
Assembly Member Ward's legislation revises California's controlled substances research approval process, modifying how the Research Advisory Panel reviews and oversees studies involving Schedule I and II substances. The bill requires panel review of research projects conducted in California that administer these controlled substances to human and animal subjects, while establishing new criteria for expedited application processing.
The legislation creates a streamlined approval pathway for research projects that meet specific requirements, including independent peer review, FDA investigational drug application approval where applicable, and institutional review board authorization. Under these provisions, the panel chair may assign two or more members to evaluate eligible applications without requiring full panel votes. The bill also maintains confidentiality protections by extending until January 2029 the panel's authorization to hold closed sessions when reviewing sensitive research information.
To ensure appropriate oversight, the legislation outlines conditions under which the panel may withdraw project approval, such as concerns about subject safety or potential controlled substance diversion. Researchers must receive written notice and at least 10 days to address any issues before approval can be withdrawn. The panel must continue providing annual reports to the Legislature and Governor detailing approved projects and their outcomes.
The measure updates the panel's composition and operations, specifying membership requirements from state agencies, universities, and medical professionals while maintaining existing provisions for record-keeping of controlled substance receipts and usage. These changes aim to balance research advancement with necessary safeguards around controlled substance studies.
This bill was recently introduced. Email the authors to let them know what you think about it.
Introduced By
 Cecilia Aguiar-CurryD Assembly Member | Committee Member |  Not Contacted | |
 Heath FloraR Assembly Member | Committee Member | Not Contacted | |
 Joaquin ArambulaD Assembly Member | Committee Member | Not Contacted | |
 Chris WardD Assembly Member | Bill Author | Not Contacted | |
 Mia BontaD Assembly Member | Committee Member | Not Contacted |
- Streamlines the approval process for research involving Schedule I and II controlled substances in California.
- Requires the Research Advisory Panel to expedite review of projects with federal approval and peer review.
- Extends authorization for closed research review sessions through January 1, 2029.
- Establishes procedures for withdrawing research approval if safety concerns or drug diversion arise.
This bill was recently introduced. Email the authors to let them know what you think about it.
Introduced By
Assembly Member Ward's legislation revises California's controlled substances research approval process, modifying how the Research Advisory Panel reviews and oversees studies involving Schedule I and II substances. The bill requires panel review of research projects conducted in California that administer these controlled substances to human and animal subjects, while establishing new criteria for expedited application processing.
The legislation creates a streamlined approval pathway for research projects that meet specific requirements, including independent peer review, FDA investigational drug application approval where applicable, and institutional review board authorization. Under these provisions, the panel chair may assign two or more members to evaluate eligible applications without requiring full panel votes. The bill also maintains confidentiality protections by extending until January 2029 the panel's authorization to hold closed sessions when reviewing sensitive research information.
To ensure appropriate oversight, the legislation outlines conditions under which the panel may withdraw project approval, such as concerns about subject safety or potential controlled substance diversion. Researchers must receive written notice and at least 10 days to address any issues before approval can be withdrawn. The panel must continue providing annual reports to the Legislature and Governor detailing approved projects and their outcomes.
The measure updates the panel's composition and operations, specifying membership requirements from state agencies, universities, and medical professionals while maintaining existing provisions for record-keeping of controlled substance receipts and usage. These changes aim to balance research advancement with necessary safeguards around controlled substance studies.
Cecilia Aguiar-CurryD Assembly Member | Committee Member | Not Contacted | |
Heath FloraR Assembly Member | Committee Member | Not Contacted | |
Joaquin ArambulaD Assembly Member | Committee Member | Not Contacted | |
Chris WardD Assembly Member | Bill Author | Not Contacted | |
Mia BontaD Assembly Member | Committee Member | Not Contacted |